On 1 July 2025, Samsung Bioepis and Hanmi Pharmaceutical announced that they have jointly launched Obodence™, biosimilar to Amgen’s Prolia® (denosumab), in South Korea, at a 13% cost savings to patients compared to the reference product. This follows Korean approval of Obodence™ in April 2025.
On 2 July 2025, Samsung Bioepis also announced that it has entered into an exclusive licensing deal with Boryung to market its other denosumab biosimilar, Xbryk™ (biosimilar to Amgen’s Xgeva®) in South Korea. Xbryk™ received Korean approval in May 2025.
Celltrion’s Stoboclo® and Osenvelt™ were the first denosumab biosimilars to be approved in Korea (November 2024). In March 2025, Daewoong Pharmaceutical launched Celltrion’s Stoboclo® in Korea at a 28% discount to reference product Prolia®. Celltrion entered into a joint sales agreement with Daewoong in October 2024, under which the two companies jointly promote Celltrion’s denosumab biosimilars in Korea.